DOCSLIB.ORG

Klasifikacija ATC 2019

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

ATC 2019 ATCCode ATCDescription ATCDescriptionSI A ALIMENTARY TRACT AND METABOLISM ZDRAVILA ZA BOLEZNI PREBAVIL IN PRESNOVE A01 STOMATOLOGICAL PREPARATIONS ZDRAVILA V ZOBOZDRAVSTVU A01A Stomatological preparations Zdravila v zobozdravstvu A01AA Caries prophylactic agents Zdravila za zaščito pred zobnim kariesom A01AA01 sodium fluoride natrijev fluorid A01AA02 sodium monofluorophosphate natrijev monofluorofosfat A01AA03 olaflur olaflur A01AA04 stannous fluoride kositrov(II) fluorid A01AA30 combinations kombinacije A01AA51 sodium fluoride, combinations natrijev fluorid, kombinacije A01AB Antiinfectives and antiseptics for local oral treatment Protimikrobne učinkovine in antiseptiki za lokalno oralno zdravljenje A01AB02 hydrogen peroxide vodikov peroksid A01AB03 chlorhexidine klorheksidin A01AB04 amphotericin B amfotericin B A01AB05 polynoxylin polinoksilin A01AB06 domiphen domifen A01AB07 oxyquinoline oksikinolin A01AB08 neomycin neomicin A01AB09 miconazole mikonazol A01AB10 natamycin natamicin A01AB11 various razne učinkovine A01AB12 hexetidine heksetidin A01AB13 tetracycline tetraciklin A01AB14 benzoxonium chloride benzoksonijev klorid A01AB15 tibezonium iodide tibezonijev jodid A01AB16 mepartricin mepartricin A01AB17 metronidazole metronidazol A01AB18 clotrimazole klotrimazol A01AB19 sodium perborate natrijev perborat A01AB21 chlortetracycline klortetraciklin A01AB22 doxycycline doksiciklin A01AB23 minocycline minociklin A01AC Corticosteroids for local oral treatment Kortikosteroidi za lokalno oralno zdravljenje A01AC01 triamcinolone triamcinolon A01AC02 dexamethasone deksametazon A01AC03 hydrocortisone hidrokortizon A01AC54 prednisolone, combinations prednizolon, kombinacije A01AD Other agents for local oral treatment Druga zdravila za lokalno oralno zdravljenje A01AD01 epinephrine adrenalin A01AD02 benzydamine benzidamin A01AD05 acetylsalicylic acid acetilsalicilna kislina A01AD06 adrenalone adrenalon A01AD07 amlexanox amleksanoks A01AD08 becaplermin bekaplermin A01AD11 various razne učinkovine A02 DRUGS FOR ACID RELATED DISORDERS ZDRAVILA ZA KISLINSKO POGOJENE BOLEZNI A02A Antacids Antacidi A02AA Magnesium compounds Magnezijeve spojine Stran 1 od 130 ATC 2019 ATCCode ATCDescription ATCDescriptionSI A02AA01 magnesium carbonate magnezijev karbonat A02AA02 magnesium oxide magnezijev oksid A02AA03 magnesium peroxide magnezijev peroksid A02AA04 magnesium hydroxide magnezijev hidroksid A02AA05 magnesium silicate magnezijev silikat A02AA10 combinations kombinacije A02AB Aluminium compounds Aluminijeve spojine A02AB01 aluminium hydroxide aluminijev hidroksid A02AB02 algeldrate algeldrat A02AB03 aluminium phosphate aluminijev fosfat A02AB04 dihydroxialumini sodium carbonate dihidroksialuminijev natrijev karbonat A02AB05 aluminium acetoacetate aluminijev acetoacetat A02AB06 aloglutamol aloglutamol A02AB07 aluminium glycinate aluminijev glicinat A02AB10 combinations kombinacije A02AC Calcium compounds Kalcijeve spojine A02AC01 calcium carbonate kalcijev karbonat A02AC02 calcium silicate kalcijev silikat A02AC10 combinations kombinacije A02AD Combinations and complexes of aluminium, calcium and magnesium compounds Zdravila z aluminijem, kalcijem in magnezijem A02AD01 ordinary salt combinations običajne kombinacije soli A02AD02 magaldrate magaldrat A02AD03 almagate almagat A02AD04 hydrotalcite hidrotalcit A02AD05 almasilate almasilat A02AF Antacids with antiflatulents Antacidi s karminativi A02AF01 magaldrate and antiflatulents magaldrat in karminativi A02AF02 ordinary salt combinations and antiflatulents običajne kombinacije soli in antiflatulenti A02AG Antacids with antispasmodics Antacidi s spazmolitiki A02AH Antacids with sodium bicarbonate Antacidi z natrijevim hidrogenkarbonatom A02AX Antacids, other combinations Antacidi, druge kombinacije A02B Drugs for peptic ulcer and gastro-oesophageal reflux disease (gord) Zdravila za zdravljenje peptične razjede in gastroezofagealne refluksne bolezni (gerb) A02BA H2-receptor antagonists Antagonisti histaminskih receptorjev H2 A02BA01 cimetidine cimetidin A02BA02 ranitidine ranitidin A02BA03 famotidine famotidin A02BA04 nizatidine nizatidin A02BA05 niperotidine niperotidin A02BA06 roxatidine roksatidin A02BA07 ranitidine bismuth citrate ranitidin-bizmutov citrat (kompleks ranitidina in bizmutovega citrata) A02BA08 lafutidine lafutidin A02BA51 cimetidine, combinations cimetidin, kombinacije A02BA53 famotidine, combinations famotidin, kombinacije A02BB Prostaglandins Prostaglandini A02BB01 misoprostol mizoprostol A02BB02 enprostil enprostil A02BC Proton pump inhibitors Zaviralci protonske črpalke A02BC01 omeprazole omeprazol Stran 2 od 130 ATC 2019 ATCCode ATCDescription ATCDescriptionSI A02BC02 pantoprazole pantoprazol A02BC03 lansoprazole lansoprazol A02BC04 rabeprazole rabeprazol A02BC05 esomeprazole esomeprazol A02BC06 dexlansoprazole dekslansoprazol A02BC07 dexrabeprazole deksrabeprazol A02BC53 lansoprazole, combinations lansoprazol, kombinacije A02BC54 rabeprazole, combinations rabeprazol, combinations A02BD Combinations for eradication of Helicobacter pylori Kombinacije učinkovin za zdravljenje okužb z bakterijo Helicobacter pylori A02BD01 omeprazole, amoxicillin and metronidazole omeprazol, amoksicilin in metronidazol A02BD02 lansoprazole, tetracycline and metronidazole lansoprazol, tetraciklin in metronidazol A02BD03 lansoprazole, amoxicillin and metronidazole lansoprazol, amoksicilin in metronidazol A02BD04 pantoprazole, amoxicillin and clarithromycin pantoprazol, amoksicilin in klaritromicin A02BD05 omeprazole, amoxicillin and clarithromycin omeprazol, amoksicilin in klaritromicin A02BD06 esomeprazole, amoxicillin and clarithromycin esomeprazol, amoksicilin in klaritromicin A02BD07 lansoprazole, amoxicillin and clarithromycin lansoprazol, amoksicilin in klaritromicin A02BD08 bismuth subcitrate, tetracycline and metronidazole bizmutov subcitrat, tetraciklin in metronidazol A02BD09 lansoprazole, clarithromycin and tinidazole lansoprazol, klaritromicin in tinidazol A02BD10 lansoprazole, amoxicillin and levofloxacin lansoprazol, amoksicilin in levofloksacin A02BD11 pantoprazole, amoxicillin, clarithromycin and metronidazole pantoprazol, amoksicilin, klaritromicin in metronidazol A02BX Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) Druga zdravila za zdravljenje peptične razjede in gastroezofagealne refluksne bolezni (GERB) A02BX01 carbenoxolone karbenoksolon A02BX02 sucralfate sukralfat (aluminijev saharozni sulfat) A02BX03 pirenzepine pirenzepin A02BX04 methiosulfonium chloride metiosulfonijev klorid A02BX05 bismuth subcitrate bazični bizmutov citrat A02BX06 proglumide proglumid A02BX07 gefarnate gefarnat A02BX08 sulglicotide sulglikotid A02BX09 acetoxolone acetoksolon A02BX10 zolimidine zolimidin A02BX11 troxipide troksipid A02BX12 bismuth subnitrate bazični bizmutov nitrat A02BX13 alginic acid alginska kislina A02BX14 rebamipide rebamipid A02BX51 carbenoxolone, combinations excl. psycholeptics karbenoksolon, kombinacije brez psiholeptikov A02BX71 carbenoxolone, combinations with psycholeptics karbenoksolon, kombinacije s psiholeptiki A02BX77 gefarnate, combinations with psycholeptics gefarnat, kombinacije s psiholeptiki A02X Other drugs for acid related disorders Druga zdravila za kislinsko pogojene bolezni A03 DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS ZDRAVILA ZA ZDRAVLJENJE GASTROINTESTINALNIH FUNKCIONALNIH MOTENJ A03A Drugs for functional gastrointestinal disorders Zdravila za zdravljenje gastrointestinalnih funkcionalnih motenj A03AA Synthetic anticholinergics, esters with tertiary amino group Sintezni antiholinergiki, estri s terciarno aminoskupino A03AA01 oxyphencyclimine oksifenciklimin A03AA03 camylofin kamilofin A03AA04 mebeverine mebeverin A03AA05 trimebutine trimebutin A03AA06 rociverine rociverin A03AA07 dicycloverine dicikloverin Stran 3 od 130 ATC 2019 ATCCode ATCDescription ATCDescriptionSI A03AA08 dihexyverine diheksiverin A03AA09 difemerine difemerin A03AA30 piperidolate piperidolat A03AB Synthetic anticholinergics, quaternary ammonium compounds Sintezni antiholinergiki s kvaterno amonijevo skupino A03AB01 benzilone benzilon A03AB02 glycopyrronium glikopironium A03AB03 oxyphenonium oksifenonium A03AB04 penthienate pentienat A03AB05 propantheline propantelin A03AB06 otilonium bromide otilonijev bromid A03AB07 methantheline metantelin A03AB08 tridihexethyl tridiheksetil A03AB09 isopropamide izopropamid A03AB10 hexocyclium heksociklium A03AB11 poldine poldin A03AB12 mepenzolate mepenzolat A03AB13 bevonium bevonium A03AB14 pipenzolate pipenzolat A03AB15 diphemanil difemanil A03AB16 (2-benzhydryloxyethyl)diethyl-methylammonium iodide (2-benzhidriloksietil)dietilmetilamonijev jodid A03AB17 tiemonium iodide tiemonijev jodid A03AB18 prifinium bromide prifinijev bromid A03AB19 timepidium bromide timepedijev bromid A03AB21 fenpiverinium fenpiverinium A03AB53 oxyphenonium, combinations oksifenonium, kombinacije A03AC Synthetic antispasmodics, amides with tertiary amines Sintezni spazmolitiki, amidi s terciarno aminoskupino A03AC02 dimethylaminopropionylphenothiazine dimetilaminopropionilfenotiazin A03AC04 nicofetamide nikofetamid A03AC05 tiropramide tiropramid A03AD Papaverine and derivatives Papaverin in njegovi derivati A03AD01 papaverine papaverin A03AD02 drotaverine drotaverin A03AD30 moxaverine moksaverin A03AE Serotonin receptor antagonists Antagonisti serotoninskih receptorjev A03AE01 alosetron alosetron A03AE03 cilansetron cilansetron A03AX Other drugs for functional gastrointestinal disorders Druga zdravila za zdravljenje gastrointestinalnih
Recommended publications
  • Par Drugs and Chemicals Limited

    Par Drugs and Chemicals Limited

    +91-8048372739 PAR DRUGS AND CHEMICALS LIMITED https://www.indiamart.com/pardrugs/ We are one of the leading Manufacturer of various Inorganic Molecules such as-Magnesium Hydroxide, Aluminium Hydroxide, Magnesium & Aluminum Silicates as well the blends of these molecules such as Magaldrate, Almagate, Hydrotalcite etc. About Us Par Drugs & Chemicals Private Limited incorporated in the year 1982 and proved its competency as the known Manufacturer of various Inorganice Molecules such as- Magnesium Hydroxide, Aluminium Hydroxide, Magnesium Trisilicate, Magnesium & Aluminum Silicates as well the blends of these molecules such as Magaldrate, Almagate, Hydrotalcite etcs. Our products stand high in terms of quality and low whereas price is concerned. Mr. F. V. Savani (Marketing Director) has enabled us to gain prominent position in industry. He ensures that the customer’s needs are efficiently fulfilled in an appropriate manner and they are served as per their demands. We do not compromises in terms of quality of our range and ensure that the customers are served accordingly. Our team ensures that products are manufactured in confirmation with the specific quality standards. Packaging of our range is done carefully so that products may reach the clients end in safe manner. Regular training sessions keep our employees aware of the changes taking place in industry and ensure that they also perform accordingly. Our well-equipped infrastructure has enabled us to carry our business operations in smooth and efficient manner. We have efficiently segregated
  • The National Drugs List

    The National Drugs List

    ^ ^ ^ ^ ^[ ^ The National Drugs List Of Syrian Arab Republic Sexth Edition 2006 ! " # "$ % &'() " # * +$, -. / & 0 /+12 3 4" 5 "$ . "$ 67"5,) 0 " /! !2 4? @ % 88 9 3: " # "$ ;+<=2 – G# H H2 I) – 6( – 65 : A B C "5 : , D )* . J!* HK"3 H"$ T ) 4 B K<) +$ LMA N O 3 4P<B &Q / RS ) H< C4VH /430 / 1988 V W* < C A GQ ") 4V / 1000 / C4VH /820 / 2001 V XX K<# C ,V /500 / 1992 V "!X V /946 / 2004 V Z < C V /914 / 2003 V ) < ] +$, [2 / ,) @# @ S%Q2 J"= [ &<\ @ +$ LMA 1 O \ . S X '( ^ & M_ `AB @ &' 3 4" + @ V= 4 )\ " : N " # "$ 6 ) G" 3Q + a C G /<"B d3: C K7 e , fM 4 Q b"$ " < $\ c"7: 5) G . HHH3Q J # Hg ' V"h 6< G* H5 !" # $%" & $' ,* ( )* + 2 ا اوا ادو +% 5 j 2 i1 6 B J' 6<X " 6"[ i2 "$ "< * i3 10 6 i4 11 6! ^ i5 13 6<X "!# * i6 15 7 G!, 6 - k 24"$d dl ?K V *4V h 63[46 ' i8 19 Adl 20 "( 2 i9 20 G Q) 6 i10 20 a 6 m[, 6 i11 21 ?K V $n i12 21 "% * i13 23 b+ 6 i14 23 oe C * i15 24 !, 2 6\ i16 25 C V pq * i17 26 ( S 6) 1, ++ &"r i19 3 +% 27 G 6 ""% i19 28 ^ Ks 2 i20 31 % Ks 2 i21 32 s * i22 35 " " * i23 37 "$ * i24 38 6" i25 39 V t h Gu* v!* 2 i26 39 ( 2 i27 40 B w< Ks 2 i28 40 d C &"r i29 42 "' 6 i30 42 " * i31 42 ":< * i32 5 ./ 0" -33 4 : ANAESTHETICS $ 1 2 -1 :GENERAL ANAESTHETICS AND OXYGEN 4 $1 2 2- ATRACURIUM BESYLATE DROPERIDOL ETHER FENTANYL HALOTHANE ISOFLURANE KETAMINE HCL NITROUS OXIDE OXYGEN PROPOFOL REMIFENTANIL SEVOFLURANE SUFENTANIL THIOPENTAL :LOCAL ANAESTHETICS !67$1 2 -5 AMYLEINE HCL=AMYLOCAINE ARTICAINE BENZOCAINE BUPIVACAINE CINCHOCAINE LIDOCAINE MEPIVACAINE OXETHAZAINE PRAMOXINE PRILOCAINE PREOPERATIVE MEDICATION & SEDATION FOR 9*: ;< " 2 -8 : : SHORT -TERM PROCEDURES ATROPINE DIAZEPAM INJ.
  • Specifications of Approved Drug Compound Library

    Specifications of Approved Drug Compound Library

    Annexure-I : Specifications of Approved drug compound library The compounds should be structurally diverse, medicinally active, and cell permeable Compounds should have rich documentation with structure, Target, Activity and IC50 should be known Compounds which are supplied should have been validated by NMR and HPLC to ensure high purity Each compound should be supplied as 10mM solution in DMSO and at least 100µl of each compound should be supplied. Compounds should be supplied in screw capped vial arranged as 96 well plate format.
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report

    Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report

    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
  • Safety Data Sheet

    Safety Data Sheet

    SAFETY DATA SHEET 1. Identification Product identifier TWINRIX ADULT Other means of identification Synonyms TWINRIX ADULT INJECTION 720 EL U AND 20 MCG/ML * TWINRIX SUSPENSION FOR INJECTION * TWINRIX ADULT PRE-FILLED SYRINGE * TWINRIX ERWACHSENE AMPULLE MIT 1 ML SUSPENSION * TWINRIX ERWACHSENE FERTIGSPRITZE MIT 1 ML SUSPENSION * HAB ADULT (720/20) * COMBINED HEPATITIS A/HEPATITIS B VACCINE * TWINRIX VACUNA COMBINADA ANTIHEPATITIS A Y B * TWINRIX VACUNA CONTRA LA HEPATITIS A Y B * TWINRIX ADULTO * AMBIRIX * HEPATITIS A VIRUS ANTIGEN (HM175) AND r-DNA HEPATITIS B SURFACE ANTIGEN (HBsAg) COMBINED VACCINE Recommended use Medicinal Product This safety data sheet is written to provide health, safety and environmental information for people handling this formulated product in the workplace. It is not intended to provide information relevant to medicinal use of the product. In this instance patients should consult prescribing information/package insert/product label or consult their pharmacist or physician. For health and safety information for individual ingredients used during manufacturing, refer to the appropriate safety data sheet for each ingredient. Recommended restrictions No other uses are advised. Manufacturer/Importer/Supplier/Distributor information COMPANY NAME GlaxoSmithKline US Address: 5 Moore Drive Research Triangle Park, NC 27709 USA Telephone: +1-888-825-5249 (General Inquiries) Email: [email protected] Website: www.gsk.com EMERGENCY CONTACTS CHEMTREC EMERGENCY NUMBERS Telephone: +(1) 703 527 3887 (International) 24/7; multi-language response Contract Number: CCN9484 VERISK 3E GLOBAL INCIDENT RESPONSE Telephone: +(1) 760 476 3971 (In country) +(1) 760 476 3962 or +(1) 866 519 4752 (International) 24/7; multi-language response Contract Number: 334878 2.
  • Tanibirumab (CUI C3490677) Add to Cart

    Tanibirumab (CUI C3490677) Add to Cart

    5/17/2018 NCI Metathesaurus Contains Exact Match Begins With Name Code Property Relationship Source ALL Advanced Search NCIm Version: 201706 Version 2.8 (using LexEVS 6.5) Home | NCIt Hierarchy | Sources | Help Suggest changes to this concept Tanibirumab (CUI C3490677) Add to Cart Table of Contents Terms & Properties Synonym Details Relationships By Source Terms & Properties Concept Unique Identifier (CUI): C3490677 NCI Thesaurus Code: C102877 (see NCI Thesaurus info) Semantic Type: Immunologic Factor Semantic Type: Amino Acid, Peptide, or Protein Semantic Type: Pharmacologic Substance NCIt Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells, while VEGF is overexpressed in many tumors and is correlated to tumor progression. PDQ Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor
  • Novel and Effective Almagate Enema for Hemorrhagic Chronic Radiation Proctitis and Its Risk Factors

    Novel and Effective Almagate Enema for Hemorrhagic Chronic Radiation Proctitis and Its Risk Factors

    DOI:http://dx.doi.org/10.7314/APJCP.2016.17.2.631 Novel and Effective Almagate Enema for Hemorrhagic Chronic Radiation Proctitis and its Risk Factors RESEARCH ARTICLE Novel and Effective Almagate Enema for Hemorrhagic Chronic Radiation Proctitis and Risk Factors for Fistula Development Zi-Xu Yuan1,2,3&, Teng-Hui Ma1&, Qing-Hua Zhong1, Huai-Ming Wang1, Xi-Hu Yu 1,3, Qi-Yuan Qin1, Li-Li Chu1, Lei Wang1,3*, Jian-Ping Wang1,3* Abstract Radiation proctitis is a common complication after radiotherapy for pelvic malignant tumors. This study was conducted to assess the efficacy of novel almagate enemas in hemorrhagic chronic radiation proctitis (CRP) and evaluate risk factors related to rectal deep ulcer or fistula secondary to CRP. All patients underwent a colonoscopy to confirm the diagnosis of CRP and symptoms were graded. Typical endoscopic and pathological images, risk factors, and quality of life were also recorded. A total of 59 patients were enrolled. Gynecological cancers composed 93.1% of the primary malignancies. Complete or obvious reduction of bleeding was observed in 90% (53/59) patients after almagate enema. The mean score of bleeding improved from 2.17 to 0.83 (P<0.001) after the enemas. The mean response time was 12 days. No adverse effects were found. Moreover, long-term successful rate in controlling bleeding was 69% and the quality of life was dramatically improved (P=0.001). The efficacy was equivalent to rectal sucralfate, but the almagate with its antacid properties acted more rapidly than sucralfate. Furthermore, we firstly found that moderate to severe anemia was the risk factor of CRP patients who developed rectal deep ulcer or fistulas P( = 0.015).
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1

    PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1

    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
  • Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Cr

    Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Cr

    Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Crizotinib (PF-02341066) 1 4 55 Docetaxel 1 5 98 Anastrozole 1 6 25 Cladribine 1 7 23 Methotrexate 1 8 -187 Letrozole 1 9 65 Entecavir Hydrate 1 10 48 Roxadustat (FG-4592) 1 11 19 Imatinib Mesylate (STI571) 1 12 0 Sunitinib Malate 1 13 34 Vismodegib (GDC-0449) 1 14 64 Paclitaxel 1 15 89 Aprepitant 1 16 94 Decitabine 1 17 -79 Bendamustine HCl 1 18 19 Temozolomide 1 19 -111 Nepafenac 1 20 24 Nintedanib (BIBF 1120) 1 21 -43 Lapatinib (GW-572016) Ditosylate 1 22 88 Temsirolimus (CCI-779, NSC 683864) 1 23 96 Belinostat (PXD101) 1 24 46 Capecitabine 1 25 19 Bicalutamide 1 26 83 Dutasteride 1 27 68 Epirubicin HCl 1 28 -59 Tamoxifen 1 29 30 Rufinamide 1 30 96 Afatinib (BIBW2992) 1 31 -54 Lenalidomide (CC-5013) 1 32 19 Vorinostat (SAHA, MK0683) 1 33 38 Rucaparib (AG-014699,PF-01367338) phosphate1 34 14 Lenvatinib (E7080) 1 35 80 Fulvestrant 1 36 76 Melatonin 1 37 15 Etoposide 1 38 -69 Vincristine sulfate 1 39 61 Posaconazole 1 40 97 Bortezomib (PS-341) 1 41 71 Panobinostat (LBH589) 1 42 41 Entinostat (MS-275) 1 43 26 Cabozantinib (XL184, BMS-907351) 1 44 79 Valproic acid sodium salt (Sodium valproate) 1 45 7 Raltitrexed 1 46 39 Bisoprolol fumarate 1 47 -23 Raloxifene HCl 1 48 97 Agomelatine 1 49 35 Prasugrel 1 50 -24 Bosutinib (SKI-606) 1 51 85 Nilotinib (AMN-107) 1 52 99 Enzastaurin (LY317615) 1 53 -12 Everolimus (RAD001) 1 54 94 Regorafenib (BAY 73-4506) 1 55 24 Thalidomide 1 56 40 Tivozanib (AV-951) 1 57 86 Fludarabine
  • Multiple Technology Appraisal Avatrombopag and Lusutrombopag

    Multiple Technology Appraisal Avatrombopag and Lusutrombopag

    Multiple Technology Appraisal Avatrombopag and lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing an elective procedure [ID1520] Committee papers © National Institute for Health and Care Excellence 2019. All rights reserved. See Notice of Rights. The content in this publication is owned by multiple parties and may not be re-used without the permission of the relevant copyright owner. NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE MULTIPLE TECHNOLOGY APPRAISAL Avatrombopag and lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing an elective procedure [ID1520] Contents: 1 Pre-meeting briefing 2 Assessment Report prepared by Kleijnen Systematic Reviews 3 Consultee and commentator comments on the Assessment Report from: • Shionogi 4 Addendum to the Assessment Report from Kleijnen Systematic Reviews 5 Company submission(s) from: • Dova • Shionogi 6 Clarification questions from AG: • Questions to Shionogi • Clarification responses from Shionogi • Questions to Dova • Clarification responses from Dova 7 Professional group, patient group and NHS organisation submissions from: • British Association for the Study of the Liver (BASL) The Royal College of Physicians supported the BASL submission • British Society of Gastroenterology (BSG) 8 Expert personal statements from: • Vanessa Hebditch – patient expert, nominated by the British Liver Trust • Dr Vickie McDonald – clinical expert, nominated by British Society for Haematology • Dr Debbie Shawcross – clinical expert, nominated by Shionogi © National Institute for Health and Care Excellence 2019. All rights reserved. See Notice of Rights. The content in this publication is owned by multiple parties and may not be re-used without the permission of the relevant copyright owner. MTA: avatrombopag and lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing an elective procedure Pre-meeting briefing © NICE 2019.
  • Immune Thrombocytopenia in Adults: Modern Approaches to Diagnosis and Treatment

    Immune Thrombocytopenia in Adults: Modern Approaches to Diagnosis and Treatment

    Published online: 2019-12-12 275 Immune Thrombocytopenia in Adults: Modern Approaches to Diagnosis and Treatment Hanny Al-Samkari, MD1 David J. Kuter, MD, DPhil1 1 Division of Hematology, Massachusetts General Hospital, Harvard Address for correspondence Hanny Al-Samkari, MD, Division of Medical School, Boston, Massachusetts Hematology, Massachusetts General Hospital, Suite 118, Room 112, Zero Emerson Place, Boston, MA 02114 Semin Thromb Hemost 2020;46:275–288. (e-mail: [email protected]). Abstract Immune thrombocytopenia (ITP) is an autoimmune bleeding disorder affecting approximately 1 in 20,000 people. Patients typically present with clinically benign mucocutaneous bleeding, but morbid internal bleeding can occur. Diagnosis remains clinical, possible only after ruling out other causes of thrombocytopenia through history and laboratory testing. Many adult patients do not require treatment. For those requiring intervention, initial treatment of adult ITP is with corticosteroids, intravenous immunoglobulin, or intravenous anti-RhD immune globulin. These agents are rapid- acting but do not result in durable remissions in most patients. No corticosteroid has Keywords demonstrated superiority to others for ITP treatment. Subsequent treatment of adult ► platelets ITP is typically with thrombopoietin receptor agonists (TPO-RAs; romiplostim or ► immune eltrombopag), rituximab, or splenectomy. TPO-RAs are newer agents that offer an thrombocytopenia excellent response rate but may require prolonged treatment. The choice between ► diagnosis subsequent treatments involves consideration of operative risk, risk of asplenia, drug ► treatment side-effects, quality-of-life issues, and financial costs. Given the efficacy of medical ► corticosteroids therapies and the rate of spontaneous remission in the first year after diagnosis, ► intravenous splenectomy is frequently deferred in modern ITP treatment algorithms.
  • Prohibited Substances List

    Prohibited Substances List

    Prohibited Substances List This is the Equine Prohibited Substances List that was voted in at the FEI General Assembly in November 2009 alongside the new Equine Anti-Doping and Controlled Medication Regulations(EADCMR). Neither the List nor the EADCM Regulations are in current usage. Both come into effect on 1 January 2010. The current list of FEI prohibited substances remains in effect until 31 December 2009 and can be found at Annex II Vet Regs (11th edition) Changes in this List : Shaded row means that either removed or allowed at certain limits only SUBSTANCE ACTIVITY Banned Substances 1 Acebutolol Beta blocker 2 Acefylline Bronchodilator 3 Acemetacin NSAID 4 Acenocoumarol Anticoagulant 5 Acetanilid Analgesic/anti-pyretic 6 Acetohexamide Pancreatic stimulant 7 Acetominophen (Paracetamol) Analgesic/anti-pyretic 8 Acetophenazine Antipsychotic 9 Acetylmorphine Narcotic 10 Adinazolam Anxiolytic 11 Adiphenine Anti-spasmodic 12 Adrafinil Stimulant 13 Adrenaline Stimulant 14 Adrenochrome Haemostatic 15 Alclofenac NSAID 16 Alcuronium Muscle relaxant 17 Aldosterone Hormone 18 Alfentanil Narcotic 19 Allopurinol Xanthine oxidase inhibitor (anti-hyperuricaemia) 20 Almotriptan 5 HT agonist (anti-migraine) 21 Alphadolone acetate Neurosteriod 22 Alphaprodine Opiod analgesic 23 Alpidem Anxiolytic 24 Alprazolam Anxiolytic 25 Alprenolol Beta blocker 26 Althesin IV anaesthetic 27 Althiazide Diuretic 28 Altrenogest (in males and gelidngs) Oestrus suppression 29 Alverine Antispasmodic 30 Amantadine Dopaminergic 31 Ambenonium Cholinesterase inhibition 32 Ambucetamide Antispasmodic 33 Amethocaine Local anaesthetic 34 Amfepramone Stimulant 35 Amfetaminil Stimulant 36 Amidephrine Vasoconstrictor 37 Amiloride Diuretic 1 Prohibited Substances List This is the Equine Prohibited Substances List that was voted in at the FEI General Assembly in November 2009 alongside the new Equine Anti-Doping and Controlled Medication Regulations(EADCMR).